Please sign in to follow a disease.
Histiocytic and dendritic cell neoplasm
MONDO:0006247Rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. They can occur at any age and show no significant variations in geographical distribution. This category includes the histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitading dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor, and dendritic cell sarcoma, not otherwise specified. (WHO, 2001)
Also known as: histiocytic and Dendritic cell neoplasms, histiocytic and Dendritic cell tumors, histiocytic and Dendritic cell tumours, histiocytic and dendritic cell neoplasm, histiocytic and dendritic cell, histiocytic and dendritic cell cancer, histiocytic and dendritic cell tumor, histiocytic and dendritic cell tumour
1927 clinical trials for this condition and its sub-types, 9 tagged with Histiocytic and dendritic cell neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Histiocytic and dendritic cell neoplasm
-
Dendritic cell tumor 0 trials · 91 incl. sub-types
3 sub-types
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Reticulum cell sarcoma 0 trials
-
Histiocytic sarcoma 9 trials
Most studied deeper sub-types
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a lower dose of a transplant drug be better for blood cancer patients?
Disease control Recruiting nowThis study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat blood cancers in new trial
Disease control Recruiting nowThis early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could this pill tame rare immune tumors?
Disease control Recruiting nowThis study tests a drug called ulixertinib for people with histiocytic neoplasms, a rare group of disorders where immune cells form tumors. The drug is taken as a pill twice daily. Researchers want to see if it can shrink tumors and control the disease. The trial will enroll 38 a…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Last-Resort drug access opens for rare tumor patients
Disease control Expanded accessThis program provides mirdametinib to individual patients with serious, life-threatening conditions like neurofibromatosis type 1 tumors or other MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. Each case requires approval from the comp…
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New PET tracer could spot Hard-to-See cancers
Knowledge-focused Recruiting nowThis early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it shows up on PET/CT scans in people with certain blood cancers (like multiple myeloma and non-Hodgkin lymphoma) and rare immune cell tumors. About 30 participants will get the agent a…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New registry aims to unlock mysteries of rare histiocyte disorders
Knowledge-focused Recruiting nowThis study creates a registry for people with Erdheim-Chester disease and related histiocytoses. Researchers will collect medical information and patient experiences over time to better understand these rare conditions. Up to 500 participants will be enrolled, and some may be ask…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC